Effektivnost' i bezopasnost' preparata Ekstimiya®, novogo pegilirovannogo filgrastima: rezul'taty otkrytogo sravnitel'nogo klinicheskogo issledovaniya II fazy patsientov s rakom molochnoy zhelezy, poluchayushchikh mielosupressivnuyu khimioterapiyu


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article is dedicated to the prevention and treatment of neutropenia associated with myelosuppressive chemotherapy in patients with malignant tumors, particularly breast cancer. For the prevention and treatment of neutropenia, recombinant drugs of human granulocyte colony stimulating factor are used for the last 20 years. The implementation of Extimia®, unique domestic drug of pegylated filgrastim (empegfilgrastim) in clinical practice would provide more available modern drug against neutropenia, with advantages over other pegylated filgrastim, for the target population of patients with cancer receiving myelosuppressive chemotherapy.

Texto integral

Acesso é fechado

Bibliografia

  1. Чиссов В.И., В.В. Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). М., 2013.
  2. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. New Engi J Med 1991;325:164–70.
  3. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008;97(10):4167-83.
  4. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20(3):727-31.
  5. Terashi К, Oka M, Ohdo S, et al. Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients. Antimicrob Agents Chemother 1999;43:21-4.
  6. Trillet-Lenoir V, Green J, Manegold С, et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-24.
  7. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23(6):1178-84.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2013

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies